Diesel europeu duplica de valor e ameaça afetar todos os preços

[Shevet]

Recebi ontem esta info de um site que subscrevo!!!

Será que tem algum potêncial??

Para quem acompanha as penny, já ouviram falar desta empresa??


"Company Description

Pluristem Life Systems, Inc. is a Nevada corporation with headquarters and research and development center located in Haifa, Israel. The Company specializes in the production of stem cell based therapeutic products to improve the engraftment of hematopoietic stem cells (HSCs) in bone marrow transplants and the ex-vivo expansion of HSCs found in umbilical cord blood. Pluristem’s first products, PLX-I and PLX-II, target a critical global shortfall of matched tissue for BMT. However, Pluristem intends to focus initially on the development of PLX-I as it is an allogeneic product and the mesenchymal stem cells (MSCs) used in the product have the ability to differentiate into a variety of cells that can be used for non-hematological ailments.



Pluristem’s product, PLX-I, derived from the Company’s PluriX™ technology, has the potential to enable umbilical-cord blood to become an alternative to bone marrow transplant (BMT), eliminating the currently deficient BMT search-and-match process. Since we initiated coverage on the Company in September 2006, we believe Pluristem has made significant strides with its technology, documented, in part, by the fact that they were invited to present data at the American Society of Hematology (ASH) on December 10, 2006, in Orlando, Florida. We also believe the Company is negotiating collaborations with other companies and scientific entities for using PLX cells in addressing a variety of ailments such as stroke and limb ischemia (lack of blood supply). This is because the stem cells expanded in Pluristem’s PluriX reactor are multipotent and potentially able to differentiate into a variety of other cells, tissues and organs. Additionally, we believe these cells are also immune-privileged: the tissues and organs resulting from the differentiation of these cells are in a position where the recipient’s immune system has learned to accept the “foreign” organ as “self” without the need for permanent immunosuppression.



Although we believe these relationships are early in negotiations, the fact that these negotiations are even occurring reinforces our belief that Pluristem’s technology can support cells that will potentially serve as products for a variety of multibillion-dollar markets. We believe Pluristem will pursue out-licensing and other arrangements for other indications while focusing on bringing PLX-I to the market as an alternative to BMT for blood cancers such as leukemia. We believe that at Pluristem’s current market value of approximately $3.8 million, speculative, risk-tolerant, patient investors could potentially see a significant upside relative to a downside of losing their entire investment. We believe this is true despite the fact that Pluristem will need to raise additional capital in the spring of 2007. One only need examine comparable companies such as Osiris Therapeutics, Inc. (NASDAQ:OSRI) and ViaCell (NASDAQ:VIAC), which have an average value of approximately $375 million, to see the potential upside for Pluristem."



Cumps
Shevet